Floatz logo

Docetaxel

Docetaxel

Zhuhai Beihai Biotech Co., LtdSmall moleculePhase 3Dormant
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Docetaxel cohort.

Asset / SponsorPhaseRating
bh009
Zhuhai Beihai Biotech Co., Ltd
Phase 3BB
Catequentinib
The First People's Hospital of Lianyungang
Phase 2CCC
Nivolumab
Peking University Cancer Hospital & Institute
Phase 2CCC

Same molecule, other indications

Docetaxel is also rated in:

prostate neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
pancreatic adenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →